|
Volumn 7, Issue 6 SUPPL., 2012, Pages 136-138
|
Global update: UK
|
Author keywords
[No Author keywords available]
|
Indexed keywords
DERMATOLOGICAL AGENT;
UNCLASSIFIED DRUG;
VAVELTA;
ARTICLE;
CLINICAL EFFECTIVENESS;
CLINICAL PRACTICE;
CYTOMEGALOVIRUS INFECTION;
EMBRYONIC STEM CELL;
EPIDERMOLYSIS BULLOSA;
EPSTEIN BARR VIRUS INFECTION;
FUNDING;
HEALTH PROGRAM;
HUMAN;
MEDICAL SOCIETY;
ORGANIZATIONAL DOWNSIZING;
ORGANIZATIONAL EFFICIENCY;
PRIORITY JOURNAL;
PRODUCT DEVELOPMENT;
PROGRAM DEVELOPMENT;
REGENERATIVE MEDICINE;
SKIN INJURY;
STEM CELL RESEARCH;
STEM CELL TRANSPLANTATION;
TRANSLATIONAL RESEARCH;
UNITED KINGDOM;
COOPERATIVE BEHAVIOR;
GREAT BRITAIN;
HUMANS;
REGENERATIVE MEDICINE;
STEM CELL RESEARCH;
|
EID: 84870691760
PISSN: 17460751
EISSN: 1746076X
Source Type: Journal
DOI: 10.2217/rme.12.73 Document Type: Article |
Times cited : (2)
|
References (0)
|